Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool

Cancer Nursing

Volumn 34, Issue 4, 2011, Pages

  Tofthagen, Cindy S ^a,b   McMillan, Susan C ^a   Kip, Kevin E ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b NONE

Author keywords

Quality of life; Symptom assessment

Indexed keywords

CISPLATIN; DOCETAXEL; OXALIPLATIN; PACLITAXEL;

ACCURACY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY ASSESSMENT TOOL; CLINICAL ASSESSMENT TOOL; CONTENT VALIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DISTRESS SYNDROME; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NEUROPATHY; OUTPATIENT; PRIORITY JOURNAL; PSYCHOMETRY; RELIABILITY; SELF REPORT; TEST RETEST RELIABILITY; VALIDITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NURSING ASSESSMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PSYCHOMETRICS; QUALITATIVE RESEARCH; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 79959668788     PISSN: 0162220X     EISSN: 15389804     Source Type: Journal    
DOI: 10.1097/NCC.0b013e31820251de     Document Type: Article

References (26)

1. Visovsky C. Chemotherapy-induced peripheral neuropathy. Cancer Invest. 2003;21(3):439-451. (Pubitemid 37059093)
2. Wickham R. Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clin J Oncol Nurs. 2007;11(3): 361-376.
3. University of Florida Shands Cancer Center. Peripheral neuropathy. http://www.ufscc.ufl.edu/Patient/content.aspx?section=ufscc&id=23151. Accessed October 1, 2008.
4. American Cancer Society. Cancer Facts and Figures 2008. http://www. cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed October 1, 2008.
5. Wilkes G. Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs. 2007;23(3):162-173.
6. Bakitas MA. Background noise: The experience of chemotherapy-induced peripheral neuropathy. Nurs Res. 2007;56(5):323-331.
7. Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci. 2006;7(10):797-809. (Pubitemid 44435262)
8. Ostchega Y, Donohue M, Fox N. High-dose cisplatin-related peripheral neuropathy. Cancer Nurs. 1988;11(1):23-32.
9. Kasper D, Fauci A, Longo D, Braunwald E, Hauser S, Jameson J, eds. Harrison's Principles of Internal Medicine. 16th ed: New York:McGraw-Hill Companies, Inc; 2005.
10. Ocean A, Vahdat L. Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies. Support Care Cancer. Sep 2004;12(9): 619-625. (Pubitemid 39280311)
11. Dunlap B, Paice JA. Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement. J Support Oncol. Sep 2006;4(8): 398-399. (Pubitemid 44541015)
12. Choi J, Kong K, Mozaffar T, Holcombe R. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs. 2006;17(1):103-105.
13. Kaley TJ, Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol. Apr 2009;145(1):3-14.
14. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer TherapyVTaxane (FACT-Taxane). Cancer. 2003;98(4): 822-831. (Pubitemid 36959280)
15. Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxelYinduced neurologic symptoms: A gynecologic oncology group study. Int J Gynecol Cancer. 2007; 17(2):387-393. (Pubitemid 46426765)
16. Kopec J, Land S, Cecchini R, et al. Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Support Oncol. 2006;4(8):W1-W8.
17. Almadrones L, McGuire DB, Walczak JR, Florio CM, Tian C. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A gynecologic oncology group study. Oncol Nurs Forum. 2004;31(3):615-623.
18. Postma TJ, Aaronson NK, Heimans JJ, et al. The development of an EORTC Quality Of Life Questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer. May 2005;41(8): 1135-1139. (Pubitemid 40725571)
19. Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology GroupYNeurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13(6):741-748. (Pubitemid 38235217)
20. Lenz ER, Pugh LC, Milligan RA, Gift A, Suppe F. The middle-range theory of unpleasant symptoms: An update. Adv Nurs Sci. 1997;19(3): 14-27. (Pubitemid 127460653)
21. Lenz ER, Suppe F, Gift AG, Pugh LC, Milligan RA. Collaborative development of middle-range nursing theories: Toward a theory of unpleasant symptoms. Adv Nurs Sci. 1995;17(3):1-13.
22. Tofthagen C. Patient perceptions associated with chemotherapy induced peripheral neuropathy. Clin J Oncol Nurs. 2010;14(3):e22-e28.
23. Grant JS, Davis LL. Selection and use of content experts for instrument development. Res Nurs Health. 1997;20(3):269-274.
24. Wynd CA, Schmidt B, Schaefer MA. Two quantitative approaches for estimating content validity. West J Nurs Res. 2003;25(5):508-518. (Pubitemid 38569354)
25. University of Texas at Austin. Differences among the Forcast, Flesch- Kincaid, and Flesch Reading Ease Formulas. http://www.utexas.edu/disability/ai/ resource/readability/manual/forcast-versus-flesch-English.html. Accessed August 12, 2010.
26. Waltz C, Strickland O, Lenz E. Measurement in Nursing and Health Research. 3rd ed. New York: Springer Publishing Company; 2005.